Treatment rationale and study design for a randomized trial of pemetrexed/carboplatin followed by maintenance pemetrexed versus paclitaxel/carboplatin/bevacizumab followed by maintenance bevacizumab in patients with advanced non-small-cell lung cancer of nonsquamous histology

Clinical Lung Cancer

Volumn 11, Issue 5, 2010, Pages 352-357

  Zinner, Ralph ^a   Saxman, Scott ^b   Peng, Guangbin ^b   Monberg, Matthew ^b   Ortuzar, Waldo ^b  

^a UNIVERSITY OF TEXAS   (United States)

^b Lilly USA   (United States)

Author keywords

Chemotherapy naive; G4PFS; Open label; Progression free survival

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CIMETIDINE; CYANOCOBALAMIN; DEXAMETHASONE; DIPHENHYDRAMINE; FOLIC ACID; PACLITAXEL; PEMETREXED; RANITIDINE;

ADVANCED CANCER; AREA UNDER THE CURVE; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE SEQUENCE; HAZARD RATIO; HUMAN; HUMAN TISSUE; LOG RANK TEST; LUNG NON SMALL CELL CANCER; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; OPEN STUDY; PATIENT SELECTION; PHASE 3 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; STUDY DESIGN; TREATMENT PLANNING;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL PROTOCOLS; DRUG ADMINISTRATION SCHEDULE; FEMALE; GLUTAMATES; GUANINE; HUMANS; LUNG NEOPLASMS; MALE; NEOPLASM STAGING; PACLITAXEL; PATIENT SELECTION; RESEARCH DESIGN;

EID: 77957037908     PISSN: 15257304     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLC.2010.n.045     Document Type: Article

References (44)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin 2009; 59:225-249
2. Lustberg MB, Edelman MJ. Optimal duration of chemotherapy in advanced non-small-cell lung cancer. Curr Treat Options Oncol 2007; 8:38-46.
3. Obasaju CK, Raju RN, Stinchcombe T, et al. Final results of a randomized phase II trial of pemetrexed (P) + carboplatin (Cb) enzastaurin (E) versus docetaxel (D) + Cb as first-line treatment of patients (pts) with stage IIIB/IV non-small-cell lung cancer (NSCLC). J Clin Oncol 2009; 27(15 suppl):416s (abstract 8037).
4. Grilli R, Oxman AD, Julian JA. Chemotherapy for advanced non-small-cell lung cancer: how much benefit is enough? J Clin Oncol 1993; 11:1866-1872
5. Marino P, Pampallona S, Preatoni A, et al. Chemotherapy vs. supportive care in advanced non-small-cell lung cancer. Results of a meta-analysis of the literature. Chest 1994; 106:861-865
6. Souquet PJ, Chauvin F, Boissel JP, et al. Polychemotherapy in advanced non-small-cell lung cancer: a meta-analysis. Lancet 1993; 342:19-21.
7. Kortsik C, Albrecht P, Elmer A. Gemcitabine and carboplatin in patients with locally advanced or metastatic non-small-cell lung cancer: a prospective phase II study. Lung Cancer 2003; 40:85-90.
8. Kosmidis P, Mylonakis N, Nicolaides C, et al. Paclitaxel plus carboplatin versus gemcitabine plus paclitaxel in advanced non-small-cell lung cancer: a phase III randomized trial. J Clin Oncol 2002; 20:3578-3585
9. Scagliotti GV, De Marinis F, Rinaldi M, et al. Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J Clin Oncol 2002; 20:4285-4291
10. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002; 346:92-98
11. Gridelli C. Histology-based treatment: a new scenario in the management of advanced non-small-cell lung cancer. Curr Opin Oncol 2009; 21:97-98
12. Gridelli C, Rossi A, de Marinis F. Pattern of care for advanced non-small-cell lung cancer in the era of histology-based treatment: A survey of the Italian Association of Thoracic Oncology (AIOT). Lung Cancer 2010; 67:339-342
13. Hirsch F, Sperafico A, Novello S, et al. The prognostic and predictive role of histology in advanced non-small-cell lung cancer: a literature review. J Thorac Oncol 2008; 3:1468-1481
14. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006; 355:2542-2550
15. Johnson DH, Fehrenbacher L, Novotny WF, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004; 22:2184-2191
16. Ciuleanu T, Brodowicz T, Zielinski C, et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet 2009; 374:1432-1440
17. Scagliotti G, Hanna N, Fossella F, et al. The differential efficacy of pemetrexed according to NSCLC histology: a review of two phase III studies. Oncologist 2009; 14:253-263
18. Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008; 26:3543-3551
19. Soon YY, Askie L, Stockler M, et al. Optimal duration of chemotherapy for advanced non-small-cell lung cancer: a systematic review and meta-analysis [abstract]. In: Proc World Conf Lung Cancer 12th annual meeting program; 2007 Sep 2-6; Seoul. J Thorac Oncol 2007; 2(8 suppl 4):S450-1 (abstract PD4-2-1).
20. Larsen H, Sorensen JB, Nielsen AL, et al. Evaluation of the optimal duration of chemotherapy in phase II trials for inoperable non-small-cell lung cancer (NSCLC). Ann Oncol 1995; 6:993-997
21. Park JO, Kim SW, Ahn JS, et al. Phase III trial of two versus four additional cycles in patients who are nonprogressive after two cycles of platinum-based chemotherapy in non small-cell lung cancer. J Clin Oncol 2007; 25:5233-5239
22. Smith IE, O'Brien ME, Talbot DC, et al. Duration of chemotherapy in advanced non-small-cell lung cancer: a randomized trial of three versus six courses of mitomycin, vinblastine, and cisplatin. J Clin Oncol 2001; 19:1336-1343
23. Socinski MA, Schell MJ, Peterman A, et al. Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage IIIB/IV non-small-cell lung cancer. J Clin Oncol 2002; 20:1335-1343
24. Socinski MA, Stinchcombe TE. Duration of first-line chemotherapy in advanced non-small-cell lung cancer: less is more in the era of effective subsequent therapies. J Clin Oncol 2007; 25:5155-5157
25. Belani CP, Perry MC, La Rocca RV, et al. Maintenance therapy (MT) with weekly paclitaxel improves outcome for advanced non-small-cell lung cancer (NSCLC) patients. J Clin Oncol 2005; 23 (16 suppl):656s (abstract 7143).
26. Brodowicz T, Krzakowski M, Zwitter M, et al. Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small-cell lung cancer: a phase III trial. Lung Cancer 2006; 52:155-163
27. Fidias PM, Dakhil SR, Lyss AP, et al. Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer. J Clin Oncol 2009; 27:591-598
28. Sekine I, Nokihara H, Sumi M, et al. Docetaxel consolidation therapy following cisplatin, vinorelbine, and concurrent thoracic radiotherapy in patients with unresectable stage III non-small-cell lung cancer. J Thorac Oncol 2006; 1:810-815
29. Scagliotti GV, Kortsik C, Dark GG, et al. Pemetrexed combined with oxaliplatin or carboplatin as first-line treatment in advanced non-small-cell lung cancer: a multicenter, randomized, phase II trial. Clin Cancer Res 2005; 11:690-696
30. Zinner RG, Fossella FV, Gladish GW, et al. Phase II study of pemetrexed in combination with carboplatin in the first-line treatment of advanced non-small-cell lung cancer. Cancer 2005; 104:2449-2456
31. Patel JD, Hensing TA, Rademaker A, et al. Phase II study of pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer. J Clin Oncol 2009; 27:3284-3289
32. Patel JD, Bonomi P, Socinski MA, et al. Treatment rationale and study design for the pointbreak study: a randomized, open-label phase III study of pemetrexed/carboplatin/bevacizumab followed by maintenance pemetrexed/ bevacizumab versus paclitaxel/carboplatin/bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer. Clin Lung Cancer 2009; 10:252-256
33. Kaplan E, Meier P. Nonparametric estimation of incomplete observations. J Am Stat Assoc 1958; 53:457-481
34. Pujol JL, Paul S, Chouaki N, et al. Survival without common toxicity criteria grade 3/4 toxicity for pemetrexed compared with docetaxel in previously treated patients with advanced non-small-cell lung cancer (NSCLC): a risk-benefit analysis. J Thorac Oncol 2007; 2:397-401.
35. Scagliotti GV, Park K, Patil S, et al. Survival without toxicity for cisplatin plus pemetrexed versus cisplatin plus gemcitabine in chemonaive patients with advanced non-small-cell lung cancer: a risk-benefit analysis of a large phase III study. Eur J Cancer 2009; 45:2298-2303
36. Therasse P, Arbuck S, Eisenhauer EA. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92:205-216
37. National Cancer Institute. Common Terminology Criteria for Adverse Events v3.0 (CTCAE). http://ctep.cancer.gov/protocolDevelopment/electronic- applications/docs/ctcaev3.pdf. Accessed: January 18, 2010.
38. Alimta (pemetrexed) [prescribing information]: Indianapolis, IN: Eli Lilly and Company; 2008.
39. Taxol (paclitaxel) [prescribing information]: Princeton, NJ: Bristol-Myers Squibb Company; 2007.
40. Goldstraw M, Shepherd F, Pass H. The International Staging System for Lung Cancer. ASCO Educational Book. ASCO; 2009:462-468
41. Rami-Porta R, Crowley JJ, Goldstraw P. The revised TNM staging system for lung cancer. Ann Thorac Cardiovasc Surg 2009; 15:4-9.
42. Cox DR. Regression models and life-tables. J R Stat Soc 1972; 74:187-220.
43. Freedman LS. Tables of the number of patients required in clinical trials using the logrank test. Stat Med 1982; 1:121-129
44. Page DL, Fleming ID, Fritz A, et al. AJCC Cancer Staging Handbook. 6th edition. New York: Springer, 2002.